PTAB Won't Hear 2 Daiichi PGRs On Cancer Antibody IP
The Patent Trial and Appeal Board said it won't review a Seagen Inc. cancer drug delivery patent being challenged by Daiichi Sankyo Inc. and AstraZeneca, noting that the drugmakers offered few...To view the full article, register now.
Already a subscriber? Click here to view full article